Scinai Immunotherapeutics
SCNI
3 hedge funds and large institutions have $102K invested in Scinai Immunotherapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0.03% more ownership
Funds ownership: 0.18% → 0.21% (+0.03%)
14% less capital invested
Capital invested by funds: $119K → $102K (-$17K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Edge Wealth Management
New York
|
+$36.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$10.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
SCNI Hedge Fund Activity: Q4 2016 in Review
3 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2016, worth a combined $102K — down 14% from $119K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SCNI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Edge Wealth Management, opening a new position worth an estimated $36.3K. The largest seller was Bank of Montreal, cutting an estimated $10.9K.
- 3 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2016, up from 2 in Q3 2016.
- Funds reported $102K of Scinai Immunotherapeutics stock for Q4 2016, down 14% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q4 2016 and 0 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q4 2016 was Edge Wealth Management, an estimated $36.3K added.
- The largest Scinai Immunotherapeutics seller in Q4 2016 was Bank of Montreal, an estimated $10.9K sold.
Based on aggregated 13F filings for Q4 2016.